| Literature DB >> 32375256 |
Gabriele Carullo1, Amer Ahmed2, Fabio Fusi3, Fabio Sciubba4, Maria Enrica Di Cocco4, Donatella Restuccia1, Umile Gianfranco Spizzirri1, Simona Saponara2, Francesca Aiello1.
Abstract
Several epidemiological studies demonstrate that moderate (red) wine consumption may afford protection against cardiovascular diseases. Protection is ascribed to the biological activity of wine components, many of which, however, are discarded during winemaking. In vitro rat thoracic aorta rings contracted with phenylephrine or KCl were used to assess the vasorelaxant activity of extracts from wine pomaces (seeds and skins) of the Calabrian autochthonous grape variety Magliocco dolce (Arvino). NMR spectroscopy was used to ascertain their chemical composition. Data demonstrate that seed and skin, but not must, extracts are capable of relaxing vascular preparations in an endothelium-dependent manner, similarly to the red wine extract, due to the presence of comparable amounts of bioactive constituents. In rings pre-contracted with 20-30 mM KCl, only seed extracts showed a moderate relaxation. The most efficacious vasodilating extract (wine) showed a good antioxidant profile in both [(2,2-diphenyl-1-picrylhydrazyl)acid] radical (DPPH) and [2,2'-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid)] radical (ABTS) assays. In conclusion, winemaking from Magliocco dolce grape can provide potentially health-promoting by-products useful in cardiovascular disease management.Entities:
Keywords: TRPV1; endothelium; flavonoids; grape polyphenols; nitric oxide synthase; vasoactivity
Year: 2020 PMID: 32375256 PMCID: PMC7281491 DOI: 10.3390/ph13050087
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Figure 1Representative 1D NMR spectrum of LDC3.
Quantitative analysis of LDC extracts by NMR spectroscopy.
| Molecule | Amount (µmol/g) | ||||||
|---|---|---|---|---|---|---|---|
| LDC1 | LDC2 | LDC3 | LDC4 | LDC5 | LDC6 | ||
|
|
| - | 1.28 ± 0.04 | - | 3.56 ± 0.11 | - | 7.85 ± 0.24 |
|
| - | 1.92 ± 0.06 | - | 5.63 ± 0.17 | - | 11.40 ± 0.34 | |
|
| 22.92 ± 0.69 | 11.60 ± 0.35 | 30.90 ± 0.93 | 26.37 ± 0.79 | 30.11 ± 0.90 | 23.62 ± 0.71 | |
|
| 59.77 ± 1.79 | 3.84 ± 0.12 | 134.24 ± 4.03 | 21.33 ± 0.64 | - | - | |
|
| - | 15.12 ± 0.45 | - | - | - | - | |
|
| - | 17.04 ± 0.51 | - | - | - | - | |
|
| - | - | - | 1.67 ± 0.05 | - | - | |
|
| - | 1.68 ± 0.05 | - | 2.67 ± 0.08 | - | 10.53 ± 0.32 | |
|
| - | 1.92 ± 0.06 | - | 5.78 ± 0.17 | - | 9.51 ± 0.29 | |
|
|
| - | 14.08 ± 0.42 | 42.51 ± 1.28 | 14.37 ± 0.43 | - | - |
|
| 104.92 ± 3.15 | 66.00 ± 1.98 | 869.41 ± 26.08 | 285.33 ± 8.56 | - | - | |
|
| 369.92 ± 11.10 | 93.60 ± 2.81 | 896.94 ± 26.91 | 430.00 ± 12.90 | 309.38 ± 9.28 | 202.64 ± 6.08 | |
|
| - | 16.68 ± 0.50 | 603.18 ± 18.10 | 103.33 ± 3.10 | - | - | |
|
| - | 59.76 ± 1.79 | 857.24 ± 25.72 | 18.28 ± 0.55 | - | 51.11 ± 1.53 | |
|
| 8.54 ± 0.26 | 2.76 ± 0.08 | - | - | - | - | |
|
| 1.38 ± 0.04 | 1.20 ± 0.04 | 3.76 ± 0.11 | 3.11 ± 0.09 | 5.45 ± 0.16 | 1.36 ± 0.04 | |
|
|
| 5.19 ± 0.16 | 3.72 ± 0.11 | 67.53 ± 2.03 | 2.56 ± 0.08 | 51.05 ± 1.53 | 91.81 ± 2.75 |
|
| - | 5.16 ± 0.15 | - | - | - | - | |
|
| - | 7.20 ± 0.22 | - | - | - | - | |
|
| - | 3.72 ± 0.11 | 18.12 ± 0.54 | - | 283.64 ± 8.51 | 171.40 ± 5.14 | |
|
| 20.69 ± 0.62 | 9.84 ± 0.30 | 90.51 ± 2.72 | - | - | - | |
|
|
| 18.23 ± 0.55 | - | - | - | - | 190.42 ± 5.71 |
|
| 3497 ± 104 | 123.36 ± 3.70 | 613.65 ± 18.41 | 11081 ± 332 | 1468.15 ± 44.04 | 309.74 ± 9.29 | |
|
| - | 36.00 ± 1.08 | 597.65 ± 17.93 | - | 242.84 ± 7.29 | 234.34 ± 7.03 | |
|
|
| - | 2.72 ± 0.08 | 205.41 ± 6.16 | - | - | 17.74 ± 0.53 |
|
| 0.46 ± 0.01 | 0.72 ± 0.02 | 7.29 ± 0.22 | 3.33 ± 0.10 | 5.24 ± 0.16 | 1.13 ± 0.03 | |
LDC1 (skin extract after rosé vinification process), LDC2 (skin extract after red vinification process), LDC3 (freeze-dried red wine), LDC4 (freeze-dried red must), LDC5 (seed extract after rosé vinification), LDC6 (seed extract after red vinification process).
Figure 2Effects of LDC extracts on phenylephrine-induced contraction in either endothelium-intact or deprived rat aorta rings. Endothelium-intact (control) or -denuded (-endo) rings, pre-contracted by 0.3 µM phenylephrine, were challenged with cumulative concentrations of (A) LDC1, (B) LDC2, (C) LDC3, (E) LDC5, and (F) LDC6. Some experiments were performed in endothelium-intact rings pre-incubated with 100 µM L-NAME. (D) Traces representative of 5–6 similar experiments, showing the effects of LDC3 on endothelium-intact rings in the absence (blue trace) or presence of 100 µM L-NAME (red trace). In the ordinate scale, relaxation is reported as a percentage of the initial tension induced by phenylephrine (Phe). Data points represent mean ± SEM (n = 4–8). *P < 0.05 vs. control, one-way ANOVA or Student’s t test for unpaired samples.
Figure 3Effects of capsazepine on LDC3-induced relaxation. Endothelium-intact rings, pre-contracted by 0.3 µM phenylephrine, were challenged with cumulative concentrations of LDC3, in the absence (control) or presence of 5 µM capsazepine. In the ordinate scale, relaxation is reported as a percentage of the initial tension induced by phenylephrine (Phe). Data points represent mean ± SEM (n = 6).
Figure 4Effect of LDC extracts on high KCl-induced contraction of rat aorta rings. (A) Concentration-response curves for LDC extracts were constructed on endothelium-denuded preparations pre-contracted by 20–30 mM KCl. In the ordinate scale, relaxation is reported as percentage of the initial tension induced by KCl, taken as 100%. In the abscissa, the concentration of each drug (as specified in the legend to symbols) is reported in µg/mL. Data points represent mean ± SEM (n = 4–6). (B) Trace representative of 4 similar experiments, showing the effects of LDC1 (µg/mL) on an endothelium-denuded ring pre-contracted by 25 mM KCl (K25). The effect of 100 µM pinacidil and 100 µM sodium nitroprussiate (SNP) is also shown.
Figure 5Scavenging activity of LDC3 (- - - -) against ABTS (∎) and DPPH (▲) radicals. Ascorbic acid (w/v) (_____) was used as positive control.